Frédéric Bilan

Frédéric Bilan

Auto-generated profile, based on publicly available information

Frédéric Bilan

Service de Génétique, CHU de Poitiers 5 , 86000 Poitiers , France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2021 in Human Genetics
Verified
Journal Article
Open access
PDF file
IPIlaria Parenti
Ilaria Parenti
DLDaphné Lehalle
Daphné Lehalle
CNCaroline Nava
Caroline Nava
ETErin Torti
Erin Torti
ELElsa Leitão
Elsa Leitão
CMCyril Mignot
Cyril Mignot
Located in the critical 1p36 microdeletion region, the chromodomain helicase DNA-binding protein 5 (CHD5) gene encodes a subunit of the nucleosome remodeling and deacetylation (NuRD) complex required for neuronal development. Pathogenic variants in six of nine chromodomain (CHD) genes cause autosomal dominant neurodevelopmental disorders, while CHD5-related disorders are still unknown. Thanks to GeneMatcher and international collaborations, we assembled a cohort of 16 unrelated individuals harboring heterozygous CHD5 variants, all identified by exome sequencing. Twelve patients had de novo CHD5 variants, including ten missense and two splice site variants. Three familial cases had nonsense or missense variants segregating with speech delay, learning disabilities, and/or craniosynostosis. One patient carried a frameshift variant of unknown inheritance due to unavailability of the father. The most common clinical features included language deficits (81%), behavioral symptoms (69%), intellectual disability (64%), epilepsy (62%), and motor delay (56%). Epilepsy types were variable, with West syndrome observed in three patients, generalized tonic–clonic seizures in two, and other subtypes observed in one individual each. Our findings suggest that, in line with other CHD-related disorders, heterozygous CHD5 variants are associated with a variable neurodevelopmental syndrome that includes intellectual disability with speech delay, epilepsy, and behavioral problems as main features.

8 September 2022 in Annals of Neurology
Verified
Journal Article
Open access
KPKonrad Platzer
Konrad Platzer
HSHeinrich Sticht
Heinrich Sticht
Caleb BuppCaleb Bupp
Caleb Bupp
MGMythily Ganapathi
Mythily Ganapathi
EPElaine M. Pereira
Elaine M. Pereira
SWSonja M. Wojcik
Sonja M. Wojcik
Objective: Rare inherited missense variants in SLC32A1, the gene that encodes the vesicular gamma‐aminobutyric acid (GABA) transporter, have recently been shown to cause genetic epilepsy with febrile seizures plus. We aimed to clarify if de novo missense variants in SLC32A1 can also cause epilepsy with impaired neurodevelopment.Methods: Using exome sequencing, we identified four individuals with a developmental and epileptic encephalopathy and de novo missense variants in SLC32A1. To assess causality, we performed functional evaluation of the identified variants in a murine neuronal cell culture model.Results: The main phenotype comprises moderate‐to‐severe intellectual disability, infantile‐onset epilepsy within the first 18 months of life, and a choreiform, dystonic, or dyskinetic movement disorder. In silico modeling and functional analyses reveal that three of these variants, which are located in helices that line the putative GABA transport pathway, result in reduced quantal size, consistent with impaired filling of synaptic vesicles with GABA. The fourth variant, located in the vesicular gamma‐aminobutyric acid N‐terminus, does not affect quantal size, but increases presynaptic release probability, leading to more severe synaptic depression during high‐frequency stimulation. Thus, variants in vesicular gamma‐aminobutyric acid can impair GABAergic neurotransmission through at least two mechanisms, by affecting synaptic vesicle filling and by altering synaptic short‐term plasticity.Interpretation: This work establishes de novo missense variants in SLC32A1 as a novel cause of a developmental and epileptic encephalopathy.Summary for Social Media If Published: @platzer_k @lemke_johannes @RamiJamra @Nirgalito @GeneDx The SLC family 32 Member 1 (SLC32A1) is the only protein identified to date, that loads gamma‐aminobutyric acid (GABA) and glycine into synaptic vesicles, and is therefore also known as the vesicular GABA transporter (VGAT) or vesicular inhibitory amino acid transporter (VIAAT). Rare inherited missense variants in SLC32A1, the gene that encodes VGAT/vesicular inhibitory amino acid transporter, have recently been shown to cause genetic epilepsy with febrile seizures plus. We aimed to clarify if de novo missense variants in SLC32A1 can also cause epilepsy with impaired neurodevelopment. We report on four individuals with de novo missense variants in SLC32A1 and a developmental and epileptic encephalopathy with infantile onset epilepsy. We establish causality of the variants via in silico modeling and their functional evaluation in a murine neuronal cell culture model. SLC32A1 variants represent a novel genetic etiology in neurodevelopmental disorders with epilepsy and a new GABA‐related disease mechanism. ANN NEUROL 2022;92:958–973

1 September 2023 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
SLSara A. Lewis
Sara A. Lewis
SBSomayeh Bakhtiari
Somayeh Bakhtiari
JFJacob Forstrom
Jacob Forstrom
ABAllan Bayat
Allan Bayat
FBFrédéric Bilan
Frédéric Bilan
MKMichael C. Kruer
Michael C. Kruer
AGAP1 is an Arf1 GTPase-activating protein that regulates endolysosomal trafficking. Damaging variants have been linked to cerebral palsy and autism. We report three new cases in which individuals had microdeletion variants in AGAP1. The affected individuals had intellectual disability (3/3), autism (3/3), dystonia with axial hypotonia (1/3), abnormalities of brain maturation (1/3), growth impairment (2/3) and facial dysmorphism (2/3). We investigated mechanisms potentially underlying AGAP1 variant-mediated neurodevelopmental impairments using the Drosophila ortholog CenG1a. We discovered reduced axon terminal size, increased neuronal endosome abundance and elevated autophagy compared to those in controls. Given potential incomplete penetrance, we assessed gene–environment interactions. We found basal elevation in the phosphorylation of the integrated stress-response protein eIF2α (or eIF2A) and inability to further increase eIF2α phosphorylation with subsequent cytotoxic stressors. CenG1a-mutant flies had increased lethality from exposure to environmental insults. We propose a model wherein disruption of AGAP1 function impairs endolysosomal trafficking, chronically activating the integrated stress response and leaving AGAP1-deficient cells susceptible to a variety of second-hit cytotoxic stressors. This model may have broader applicability beyond AGAP1 in instances where both genetic and environmental insults co-occur in individuals with neurodevelopmental disorders.

1 September 2019 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
GBGara Samara Brajadenta
Gara Samara Brajadenta
Agustini UtariAgustini Utari
Agustini Utari
SPSylvie Patri
Sylvie Patri
FBFrédéric Bilan
Frédéric Bilan
SFSultana Muhammad Hussein Faradz
Sultana Muhammad Hussein Faradz
VTVincent Thoreau
Vincent Thoreau
Brajadenta GS, et al. Ann Lab Med. 2019 Sep;39(5):503-506. https://doi.org/10.3343/alm.2019.39.5.503

9 December 2021 in medRxiv
Verified
Preprint
Open access
PDF file
KPKonrad Platzer
Konrad Platzer
HSHeinrich Sticht
Heinrich Sticht
Caleb BuppCaleb Bupp
Caleb Bupp
MGMythily Ganapathi
Mythily Ganapathi
EPElaine M. Pereira
Elaine M. Pereira
SWSonja M. Wojcik
Sonja M. Wojcik
We describe four patients with a neurodevelopmental disorder and de novo missense variants in SLC32A1, the gene that encodes the vesicular GABA transporter (VGAT). The main phenotype comprises moderate to severe intellectual disability, early onset epilepsy within the first 18 months of life and a choreatic, dystonic or dyskinetic movement disorder. In silico modeling and functional analyses in cultured neurons reveal that three of these variants, which are located in helices that line the putative GABA transport pathway, result in reduced quantal size, consistent with impaired filling of synaptic vesicles with GABA. The fourth variant, located in the VGAT N-terminus, does not affect quantal size, but increases presynaptic release probability, leading to more severe synaptic depression during high frequency stimulation. Thus, variants in VGAT can impair GABAergic neurotransmission via at least two mechanisms, by affecting synaptic vesicle filling and by altering synaptic short-term plasticity. This work establishes de novo missense variants in SLC32A1 as a novel cause for a neurodevelopmental disorder with epilepsy.

25 October 2026 in Journal of Intellectual Disability Research
Verified
Journal Article
Closed access
HSHajar Souski
Hajar Souski
YBYousra Benmakhlouf
Yousra Benmakhlouf
VLValérie Lepine
Valérie Lepine
HBHouda Bekkari
Houda Bekkari
ABAmina Barakat
Amina Barakat
MMMohcine Bennani Mechita
Mohcine Bennani Mechita